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Background: The polymorphism of thymidylate synthase (TS) gene and homocysteine are
reported to have a relationship to methotrexate (MTX) metabolism, with conﬂicting results.
The aim of this study was to determine homocysteine levels and the frequency of TS gene
triple repeat (TS3R) and double repeat (TS2R) polymorphisms in a group of Turkish RA
patients and evaluate its association with MTX toxicity and disease activity.
Methods: Sixty-four patients with RA and 31 control subjects with a mean age of 48.7 ± 12.5
and 46.2 ± 13.4 years were enrolled for the study. Demographic characteristics were obtained
and a number of patients with MTX-related adverse affects were recorded in the patient
group. The homocysteine levels and TS2R/TS3R polymorphisms of the TS gene were ana-
lyzed and the distribution of genotypes according to MTX toxicity and disease activity was
determined.
Results: The demographic properties were similar between the patient and control sub-
jects.  Folic acid supplementation with a mean dose of 5 mg folic acid/week was present in
all  patients. Thirty-six of the 64 patients showed adverse effects to MTX treatment. The
respective frequency of TS2R and TS3R polymorphisms was found to be similar in the
patient and control groups. TS2R and TS3R gene polymorphisms were found to be simi-
lar  in patients with and without MTX-related adverse events. The mean homocysteine levelwas also similar in patients with and without TS gene polymorphism, but was found to
be  higher (12.45 mol/L vs 10.7 mol/L) in patients with MTX-related side effects than in
 effects. The mean level of homocysteine was correlated with levels ofpatients without sideESR  in the patient group.
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Conclusions: In conclusion, homocysteine levels might affect the disease activity and toxic-
ity  of MTX but 2R and 3R polymorphisms in the TS gene were not related with MTX-related
toxicity in RA patients receiving folate supplementation. Further studies are needed to illu-
minate the polymorphisms in other enzymes that might be responsible for the MTX toxicity
in  patients suffering from RA.
© 2015 Elsevier Editora Ltda. All rights reserved.
Polimorﬁsmo  do  gene  timidilato  sintase  e  nível  plasmático  total  de
homocisteína  em  um  grupo  de  pacientes  turcos  com  artrite  reumatoide:
relac¸ão  com  a  atividade  da  doenc¸a e  toxicidade  ao  metotrexato
Palavras-chave:
Artrite reumatoide
Timidilato sintase
Homocisteína
Polimorﬁsmo
Metotrexato
r  e  s  u  m  o
Introduc¸ão: Relata-se que o polimorﬁsmo do gene timidilato sintase (TS) e a homocisteína
têm  relac¸ão com o metabolismo do metotrexato (MTX), com achados conﬂitantes. O objetivo
deste estudo foi determinar os níveis de homocisteína e a frequência de polimorﬁsmos de
repetic¸ão tripla (TS3R) e dupla (TS2R) do gene TS em um grupo de pacientes turcos com AR
e  avaliar sua associac¸ão com a toxicidade ao MTX e a atividade da doenc¸a.
Métodos: Foram incluídos no estudo 64 pacientes com AR e 31 indivíduos no grupo controle,
com média de 48,7 ± 12,5 e 46,2 ± 13,4 anos. Foram obtidas as características demográﬁcas
e  foi registrado o número de pacientes que relataram efeitos adversos ao MTX no grupo AR.
Foram analisados os níveis de homocisteína e os polimorﬁsmos TS2R/TS3R. Foi determinada
a  distribuic¸ão de genótipos de acordo com a toxicidade ao MTX e a atividade da doenc¸a.
Resultados: Os dados demográﬁcos foram semelhantes entre os pacientes e controles. Todos
faziam suplementac¸ão de ácido fólico a uma dose média de 5 mg/semana. Dos 64 pacientes,
36  apresentaram efeitos adversos ao tratamento com MTX. Encontrou-se uma frequência
de  polimorﬁsmos TS2R e TS3R semelhante nos grupos AR e controle. Encontrou-se que os
polimorﬁsmos TS2R e TS3R eram semelhantes em pacientes com e sem eventos adversos
relacionados com o MTX. O nível médio de homocisteína também foi similar em pacientes
com  e sem polimorﬁsmo do gene TS, mas era mais elevado (12,45 mol/L vs. 10,7 mol/L)
em  pacientes com do que sem efeitos adversos relacionados com o MTX. O nível médio de
homocisteína se correlacionou com o VHS no grupo AR.
Conclusões: Os níveis de homocisteína podem afetar a atividade da doenc¸a e a toxicidade
ao  MTX, mas os polimorﬁsmos 2 R e 3 R no gene TS não se correlacionaram com a tox-
icidade ao MTX em pacientes com AR que recebem suplementac¸ão de ácido fólico. São
necessários mais estudos para esclarecer os polimorﬁsmos em outras enzimas que podem
ser  responsáveis pela toxicidade ao MTX em pacientes com AR.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Methotrexate (MTX) is the cornerstone and the most com-
monly used disease modifying anti-rheumatic drug (DMARD)
for the treatment of rheumatoid arthritis (RA). The beneﬁ-
cial effects of MTX  in RA stem primarily from two aspects
of the mechanism of action. It directly inhibits several folate
dependent enzymes such as dihydrofolate reductase and
thymidylate synthase (TS); leading to disrupted purine and
pyrimidine synthesis and extracellular release of adenosine,
a potent antiinﬂammatory agent respectively.1,2 Several stud-
ies demonstrated the effect of gene polymorphisms on MTX
efﬁcacy and safety but the available evidence is not yet
conclusive.1–13 Thymidylate synthase is an important tar-
get for methotrexate and overexpression of TS is linked to
resistance of TS-targeted drugs.14 Polymorphism of TS geneis reported to have a relationship to MTX metabolism with
conﬂicting results.3–13 Homocysteine is an aminoacid con-
taining the thiol group and is an intermediate product of the
metabolism of methionine. Some previous authors concluded
that plasma homocysteine may be important in mediating the
side effects of MTX.15–17 Increasing pharmacogenetic studies
show that a variety of gene polymorphisms including the TS-
5′UTR 3R/2R variant result in hyperhomocysteinaemia, which
could be responsible for more  common and severe MTX-
related side effects.7,17,18 Besides hyperhomocysteinaemia has
been linked to inﬂammation in RA. Homocysteine levels
are also known to be inﬂuenced by nutrients such as folic
acid and the vitamin B complex, and anti-RA drugs such as
6,7,16MTX.
The aims of this study were to determine the frequency
of TS gene double-triple repeat (2R/3R) polymorphism and
homocysteine levels and in a group of patients with RA and
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o evaluate their relationship with disease activity and MTX
oxicity.
ethods
ixty-four RA patients who  met  the ACR revised criteria19 were
ecruited from the outpatient rheumatology unit of Clinic of
hysical Medicine and Rehabilitation, Ankara Training and
esearch Hospital between February and July 2009.
Current or past treatment with MTX  was the main crite-
ion for the inclusion of RA patients into the study. Patients
ith a mean BMI  >35, aged <18, and >80 years, having B12
nd folic acid depletion and patients with these comorbid
iseases (chronic renal failure, hepatic insufﬁciency, thyroid
isease, heart failure and uncontrolled diabetes mellitus) were
ot included to the study. One hundred and four patients with
heumatoid arthritis were assessed for eligibility. Ninety-eight
atients had current or past MTX  treatment, 5 patients refused
o participate in the study and 29 patients were excluded due
o age or comorbid diseases. Therefore 64 RA patients were
ncluded to the study. Thirty-one age and sex similar (within
2 years) healthy control subjects who were the members of
he hospital staff and volunteered to participate in the study,
ere comprised. Informed consent was obtained from all the
atients and controls, and the study was approved by the
thics committee of the hospital.
Demographic characteristics including age, sex, body mass
ndex of all subjects, and disease duration and drug intake
f RA patients were recorded. All the patients underwent
 detailed clinical interview and physical examination. The
umber of patients having MTX-related adverse event was
etermined from the ﬁles and patient interviews.
linical  measurements
he numbers of tender and swollen joints as well as disease
nd treatment duration were collected from patient ﬁles. DAS
8 was calculated for each patient using well-known calcu-
ations which included the number of tender and swollen
oints, erythrocyte sedimentation rate (ESR), and patients’
lobal assessment of general health expressed on visual ana-
og scale.20 The scores of Health Assessment Questionnaire
HAQ) indicating the functional status of RA patients were
ecorded from the ﬁles.21,22 The ESR, C reactive protein (CRP),
isease Activity Score (DAS) 28 and HAQ were considered as
isease activity parameters.
aboratory  measurements
lood samples of the patients were taken to determine
emoglobin (Hb), ESR using the Westergren method, rheuma-
oid factor (RF) using nephelometric method and CRP by
urbidimetric method in RA group. The blood samples were
entrifuged and the plasma samples were frozen at −20 ◦C
ntil the analysis of homocysteine. Plasma homocysteine was
easured by enzyme-linked immunoassay according to the
anufacturer’s instructions (Axis Biochemicals, ASA Norway).
he homocysteine levels among patient and control groups
ere compared. The relationship between homocysteine level 5;5 5(6):485–492 487
and, disease characteristics and side effects was also ana-
lyzed.
Genomic  studies
Genomic DNA was prepared from peripheral blood of patients
and controls. The 2R and 3R polymorphisms of the TS gene
were analyzed by polymerase chain reaction ampliﬁcation
as described previously with slight modiﬁcations.23 The PCR
ampliﬁcation program consisted of an initial denaturation
step at 95 ◦C for 15 min, followed by 30 cycles of denaturation of
94 ◦C for 1 min, annealing at 64 ◦C for 1 min, extension at 72 ◦C
for 1 min  and a ﬁnal extension of 72 ◦C for 10 min. PCR products
were separated by 6% denaturing polyacrylamide gel elec-
trophoresis (PAGE) for 3 h at 300 V and visualized by ethidium
bromide. The allelic frequencies and genotype distributions
among patient and control groups were compared. The distri-
bution of genotypes according to disease characteristics and
side effects was also analyzed.
Statistical  analysis
Descriptive statistics were performed and indicated as
mean ± standard deviation and median (maximum–
minimum) for continuous variables. All qualitative data
are expressed as frequencies and percentages. The normality
of the distribution of continuous variables was analyzed by
Shapiro–Wilk test. Differences in genotype distribution were
tested with two sided chi-square test. The intergroup compar-
isons for continuous variables between the two  groups (with
and without polymorphism) were performed by Student t test
and Mann–Whitney U test. Spearman’s correlation test was
used to evaluate correlation between continuous variables
and Pearson’s chi square test or Fisher’s exact outcome chi
square tests were used to deﬁne the categorical variables. The
level of signiﬁcance was set to 0.05. All statistical analyses
were done using SPSS for windows version 11.5.
Results
A total of 64 RA patients and 31 control subjects were included
to the study. Demographic data of RA patients and control
subjects are presented in Table 1. There was no statistical dif-
ference between the mean age, sex and BMI  of the patient
and control groups (p > 0.05). Most patients were receiving MTX
at the time of recruitment but some had discontinued MTX
treatment due to adverse effects. Folic acid supplementation
with a mean dose of 5 mg  folic acid/weekly was recorded in all
patients.
Thirty-four (53%) patients were using MTX and other
DMARDs. 38 (59.4%) patients were using oral MTX, while 26
(40.6%) patients were on subcutaneous MTX  therapy. The
mean duration and dose of the MTX were 2 years (0.2–10) and
15 mg/week (10–20) respectively.
Thirty-six of the 64 patients (56.2%) had experienced
adverse effects to MTX  treatment, of which gastrointestinal
toxicity was the most common. MTX had been discontinued
in 12 (18.8%) patients due to adverse side effects. There was
no signiﬁcant difference in the MTX  dosage, the demographic
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Table 1 – Demographic and clinical characteristics of
patients and controls.
Patients
(n = 64)
Controls
(n = 31)
Age (mean ± SD) (years) 48.7 ± 12.5 46.2 ± 13.4
Sex (female/male) 53/11 26/05
BMI (kg/m2) 27 ± 5 27.5 ± 4.7
Duration of the disease (years) 6.5 (0.50–34)
Duration of MTX treatment
(years)
2  (0.2–10)
Concurrent DMARD treatment
(n) (%)
34  (53.1%)
Rheumatoid factor positivity
(n) (%)
41  (64.1%)
Homocysteine
(mol/L)(median)
11.2 (5–146) 10.1 (6–18)
BMI, body mass index; MTX, methotrexate; DMARD, disease-
Table 4 – The genotypic distribution according to
adverse events in patients receiving only methotrexate
treatment.
Variables Adverse effect (−)
(n = 13)
Adverse effect (+)
(n = 17)
p
TS 2R2R 3 (23.1%) 7 (41.2%)
TS 2R3R 5 (38.5%) 7 (41.2%)
TS 3R3R 5 (38.5%) 3 (17.6%)
2R3R + 3R3R 10 (76.9%) 10 (58.8%) 0.440
repeat found in the 5′ untranslated region and subjects weremodifying antirheumatic drugs.
and clinical features between the patients with and without
adverse effects during MTX  treatment (p > 0.05).
The frequencies of TS2R/TS3R polymorphisms were deter-
mined in all subjects and were found to be statistically similar
between patient and control groups (Table 2). The distribu-
tion of allele polymorphisms in regard to MTX-related adverse
events was carried out. TS2R/TS3R gene polymorphisms were
found to be similar in patients with and without MTX-related
adverse events (Table 3). In order to deﬁne the relationship
between MTX-related side effects and polymorphisms in TS
gene, we have analyzed the patients receiving only MTX treat-
ment. The distribution of TS 2R and 3R polymorphisms in
patients with and without adverse effects was again found
to be similar (p > 0.05) (Table 4).
Table 2 – The distribution of genotypes (TS polymorphisms) in 
Control (n = 31)
n (%)
RA  (n = 6
n (%
TS 2R2R 6 (19.4%) 14 (21.9
TS 2R3R 20 (64.5%) 33 (51.6
TS 3R3R 5 (16.1%) 17 (26.6
2R3R + 3R3R 25 (80.6%) 50 (78.1
TS, thymidylate synthase; CI, conﬁdence interval.
a Reference category.
Table 3 – The genotypic distribution of RA patients according to
Adverse events (−)
(n = 28)
Adverse e
(n =
TS 2R2R 4 (14.3%) 10 (27.8
TS 2R3R 14 (50.0%) 19 (52.8
TS 3R3R 10 (35.7%) 7 (19.4
2R3R + 3R3R 24 (85.7%) 26 (72.2
CI, conﬁdence interval; TS, thymidylate synthase.
a Reference category.TS, thymidylate synthase.
The distribution of disease activity parameters in regard
to allele polymorphisms was also determined. No statistical
difference among ESR, CRP, HAQ and DAS 28 values in regard
to TS 2R and 3R polymorphisms was observed in the patient
group (Table 5).
The mean plasma homocysteine levels were statistically
similar in patient and control subjects. In the patient group,
the mean homocysteine level was correlated with ESR lev-
els (p < 0.05, r = 30) and found to be signiﬁcantly higher in
patients with MTX-related side effects than in patients with-
out side effects (Table 6). The homocysteine values were also
similar in patients with and without TS gene polymorphism
(Table 7).
Discussion
The most studied polymorphisms in the TS gene was
described by Horie et al.24 The TS gene contains a tandemobserved with two tandem repeats, three tandem repeats or
heterozygous genotype. This tandem repeat region acts as an
patient and control groups.
4)
)
p  Odds ratio (% CI)
%) – 1.000a
%) 0.539 0.707 (0.234–2.137)
%) 0.593 1.457 (0.366–5.801)
%) 0.778 0.857 (0.294–2.499)
 presence of adverse events.
vents (+)
 36)
p  Odds ratio (95% CI)
%) – 1.000a
%) 0.375 0.543 (0.141–2.093)
%) 0.098 0.280 (0.062–1.266)
%) 0.195 0.433 (0.120–1.567)
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Table 5 – The distribution of disease activity parameters according to the polymorphisms in thymidylate synthase gene.
Variables 2R2R
(n = 14)
2R3R
(n  = 33)
3R3R
(n = 17)
p
HAQ (median) 0.8 (0–3) 0.6 (0–3) 0.75 (0–2.5) 0.695
DAS28 (median) 4.0 (2.1–7.5) 4.0 (1.7–7.8) 4.5 (1.9–6.9) 0.909
ESR (median) 29.0 (10.0–120.0) 30.0 (2.0–82.0) 25.0 (7.0–65.0) 0.695
CRP (median) 0.7 (0.3–10.0) 0.7 (0.1–10.5) 0.8 (0.2–4.8) 0.409
HAQ, health assessment questionnaire; DAS, disease activity score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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frequencies of this polymorphisms (5% and 6%) than in previ-
ous studies.5,18nhancer to the TS promoter and leads to an increase in TS
ctivity. The promoter enhancer region of TS gene contains
 double (2R) or a triple (3R) 28-base-pair (bp) tandem repeat
olymorphism where 3R genotype is associated with a higher
S gene expression.24,25
Our study showed that the frequency of TS2R and TS3R
olymorphisms was similar in Turkish RA patients and
ealthy control subjects. The rates of polymorphism in the
andem repeat of 5′ UTR region were signiﬁcantly lower
rom the previous studies which could be related to ethnic
ifferences.26
Previous authors reported that genotyping for TS poly-
orphism may become a useful indicator for determining
he appropriate dosage of MTX  and for monitoring MTX tox-
city in RA patients.2,6,9,11 There have been confusing data
egarding the impact of TS polymorphism on MTX treatment
esponse in RA patients, as TS is one of the enzymes in the
olate metabolic pathway that is directly inhibited by MTX. A
ower disease activity and an improved response to low dose
TX  were reported in patients having TS polymorphism.2
umagai et al.9 and Inoue et al.11 evaluated the relation-
hip between the response to MTX  and TS genotype in
apanese patients and reported a better response to MTX
n patients with 6 bp alleles in TS 3′ UTR region. But the
egarded patients in their study were on low dose (6 mg/week)
TX  therapy. On the other hand, the 3R/3R genotype was
ssociated with poor response to MTX  therapy in some pre-
ious studies.6,13 Regarding MTX  toxicity, polymorphism of
S gene was associated with occurrence of alopecia18 while
o relation between polymorphism of TS gene and MTX
oxicity was reported in other previous studies.6 Contrary
o some previous studies, the present study also showed
hat genetic polymorphisms in the TS gene did not inﬂu-
nce the disease activity or toxicity of MTX treatment in
A patients receiving folate supplementation. Grabar et al.8tudied a group of gene polymorphism including TS and
eported no relationship between polymorphisms and dis-
ase activity parameters including ESR, CRP and DAS 28
Table 6 – Homocystein levels according to the presence
of adverse effects of methotrexate in patients with AR.
Homocystein p
Adverse effects 0.024
Absent 10.7 (5.0–33.0)
Present 12.45 (6.8–146.0)values. Regarding the adverse effects due to MTX  treatment,
TS2R/3R polymorphisms were found to decrease bone marrow
toxicity in their study group.8 In the presence of risk geno-
type combinations among variants in TS and other genes, a
higher likelihood to exhibit toxicities was reported.27 Table 8
represents a review of published literature on TS gene poly-
morphisms affecting MTX  treatment and/or toxicity in RA
patients.
MTX inhibits the enzyme dihydrofolate reductase, thereby
depleting the pool of reduced folates and producing a state of
effective folate deﬁciency.1 Folic acid improves MTX  tolerabil-
ity rates without compromising efﬁcacy.1,2 5 mg/day folic acid
has been proposed to be given in all patients receiving MTX
therapy.28,29 In our study all of the patients were on concomi-
tant folic acid supplementation, which might be a limitation of
our study. It would be valuable to study these gene expressions
according to side effects of MTX, in both patients on folate
supplementation and in patients not receiving this supple-
mentation. Our study also included a relatively small number
of patients and not all of the polymorphic genes involved in
the MTX metabolism were tested. Therefore additional data
might be needed to demonstrate more  conclusive results. But
our study was not biased by genetic heterogeneity, as all the
patients were members of an ethnically homogeneous popu-
lation. We have previously studied polymorphisms in MTHFR
A1298C and C677T genes but failed to show any relationship
with toxicity of MTX in the same group of RA patients.30 The
discrepancies between previous studies and the present study
might be due to the differences in the frequencies of TS2R/3R
homozygotic polymorphisms, since our study group has lowerTable 7 – The levels of homocystein according to the
polymorphism of Thymidylate synthase gene.
Homocystein p
0.893a
TS 2R2R 11.3 (5.2–146.0)
TS 2R3R 11.0 (5.2–50.0)
TS 3R3R 11.0 (5.0–42.0)
2R3R + 3R3R 11.0 (5.0–50.0) 0.655b
TS, thymidylate synthase.
a Variance analysis among genotypes.
b Comparison between genotypes with risky allele and reference
genotype.
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Table 8 – Literature review on TS gene polymorphisms affecting MTX  treatment and/or toxicity in RA patients.
Author RA patients
(n)
Studied poly-
morphisms
MTX  efﬁcacy MTX toxicity Receiving
folic acid
Dervieux et al.26 255 TS 2R/3R (and
other genes)
ns  Increased
toxicity
Not  known
Dervieux et al.2 108 TS 2R/3R (and
other genes)
Increased
MTX
response
Not  studied 1 mg/day
Takatori et al.10 124 TS 6 bp
deletion poly-
morphism
(and other
genes)
ns  ns Not known
Derwieux et al.6 48 TS 2R/3R (and
other genes)
ns  ns + (95% of
patients)
Weisman et al.18 214 TS2R/3R 3R
(and other
genes)
ns  Increased
alopecia
+  (81% of
patients)
Grabar et al.8 213 TS 2R/3R (and
other genes)
ns  Increased
bone marrow
toxicity
+  (62–91%
patients)
Ghodke et al.5 34 TS 2R/3R and
6bp deletion
ns  ns Not known
Inoue et al.11 36 TS 6bp
deletion and
TS 2R/3R
6bp deletion
related with
CRP and
better
response to
MTX
Not studied 5 mg/week
Kumagai et al.9 105 TS 2R/3R and
6bp deletion
Poor  response
to MTX
ns Not known
Ranganathan et al.13 222 TS 1494 of
TTAAAG (and
other genes)
Not  studied ns 1–3 mg/day
Zeng et al.7 85 TS 3R/2R Not studied ns –
Present study 64 TS 2R/3R ns ns 5 mg/weekTS, thymidylate synthase; MTX, methotrexate; ns, non-signiﬁcant.
Plasma homocysteine levels were reported to be related
with inﬂammatory markers in some RA patients16,17 in accor-
dance with our data indicating a relationship between ESR and
homocysteine levels in our study group.
Previous studies on the effect of MTX  on homocysteine
concentrations in patients with RA showed a substantial
rise in homocysteine concentrations during MTX treatment,
an effect that was diminished by folate supplementation.31
Plasma homocysteine levels were measured in 105 RA patients
and patients receiving MTX  showed a persistent greater
increase in plasma homocysteine which was explained by fur-
ther enhancement of MTHFR polymorphism. These authors
concluded that plasma homocysteine may be important
in mediating the gastrointestinal side effects of MTX.15
Some previous authors speculated that impeded homo-
cysteine metabolism introduced by intracellular conversion
of folate was the mechanism of the increased frequency
of toxicities in patients with the mutant allele at C677T
polymorphism.4,29 In our study the homocysteine levels were
similar between patients and healthy control subjects which
may be due to the regular receiving of folate supplemen-
tation in all patients. Previous studies, in agreement with
our study, indicated that MTX  doses with adjuvant folicacid did not increase homocysteine levels.28 But homocys-
teine levels were found to be higher in patients with adverse
effects due to MTX than in patients without adverse effects.
This may be explained by the active disease in patients
who have to decrease or stop MTX treatment due to side
effects.
Methotrexate metabolism is complex and involves the
interaction of a number of genes in the folate pathway. In
our study, 2R and 3R polymorphisms in the TS gene were not
related with MTX efﬁcacy or toxicity in RA patients receiving
folate supplementation. We  speculate that the effects of other
genetic polymorphisms on the sensitivity to MTX toxicity may
be stronger than those of TS 2R and 3R gene polymorphisms.
However, homocysteine levels were correlated with ESR lev-
els, and found to be higher in patients with adverse effects
than in patients without these effects, which might indicate
the effect of homocysteine on disease activity and/or MTX
toxicity.
In conclusion homocysteine levels may affect the disease
activity and toxicity of MTX but 2R and 3R polymorphisms
in the TS gene were not related with MTX-related toxicity
in RA patients receiving folate supplementation. Further
larger studies are needed to illuminate the reasons and
 . 2 0 1
p
f
C
T
r
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2r e v b r a s r e u m a t o l
olymorphisms in other enzymes that might be responsible
rom clinical toxicity of MTX  in patients suffering from RA.
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